CELLINK sends bioprinted neural crest stem cells to space

In collaboration with a team of scientists at Uppsala University, CELLINK has sent 3D-bioprinted boundary cap neural crest stem cells to space.

Space exploration challenges the limits of human physiology, and advancing capabilities in spaceflight requires innovative solutions from frontline scientists across fields of physics, biology and medicine.

To study the influence of microgravity and hypergravity on living systems, CELLINK is conducting collaborative research with Uppsala University. CELLINK’s BIO X bioprinter and bioinks were used to bioprint boundary cap neural crest stem cells that were successfully launched to space on June 24. The cells were supplied by Uppsala University and printed using CELLINK Bioink and CELLINK GelMA. The samples were launched to space on Maser14 by the Swedish Space Agency.

The partnership is aiming to accelerate the development of a 3D neural stem cell system to provide insight on how gravity alterations influence cellular properties. CELLINK, the world’s first bioink company and the global leader in bioprinters and bioinks, continually seeks new partnerships and collaborations to provide researchers with emerging capabilities and innovations in the field.

For more information, please contact:

Erik Gatenholm, CEO                                                                                  Gusten Danielsson, CFO

Phone: EU +46 73 267 00 00                                                                      Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                                                 US +1 (857) 332 2138 

Email: eg@cellink.com                                                                              Email: gd@cellink.com  


CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at certifiedadviser@penser.se.

Latest press releases